Advertisement
Table 1 Demographics of HSCT donors and recipients in the discovery and validation cohorts
| Discovery cohort | Validation cohort | |||
|---|---|---|---|---|
| (n = 85 pairs) | (n = 32 pairs) | |||
| Donors | Recipients | Donors | Recipients | |
| Sex | ||||
| Female | 41 | 27 | 14 | 7 |
| Male | 44 | 58 | 18 | 25 |
| Age at transplant (years) | ||||
| Median | 48 | 52 | 53 | 55 |
| Range | 14–72 | 21–66 | 22–71 | 23–64 |
| CMV serostatus | ||||
| Positive | 38 | 43 | 14 | 11 |
| Negative | 31 | 32 | 16 | 21 |
| NA | 16 | 10 | 2 | 0 |
| Max. acute GVHD | ||||
| Absent | – | 39 | – | 15 |
| Grade I ('mild') | – | 24 | – | 3 |
| Grade II ('mild') | – | 13 | – | 5 |
| Grade III ('severe') | – | 8 | – | 7 |
| Grade IV ('severe') | – | 1 | – | 2 |
| Max. chronic GVHD | ||||
| Absent | – | 54 | – | 2 |
| Limited | – | 21 | – | 10 |
| Extensive | – | 9 | – | 3 |
| NA | – | 1 | – | 17 |
| Diagnosis | ||||
| Acute lymphoblastic leukemia | – | 1 | – | 1 |
| Acute myeloid leukemia | – | 17 | – | 8 |
| Chronic granulomatous disease | – | 1 | – | 0 |
| Chronic lymphocytic leukemia (CLL) | – | 11 | – | 0 |
| Chronic myeloid leukemia (CML) | – | 0 | – | 3 |
| Chronic myelomonocytic leukemia | – | 1 | – | 0 |
| Hodgkin lymphoma | – | 9 | – | 4 |
| Myelodysplasia (MDS) | – | 2 | – | 0 |
| MDS/CML/CLL | – | 1 | – | 0 |
| Myelofibrosis | – | 0 | – | 2 |
| Myeloproliferative syndromes/MDS | – | 0 | – | 2 |
| Myeloma | – | 3 | – | 0 |
| Non-Hodgkin lymphoma | – | 37 | – | 8 |
| Other | – | 0 | – | 4 |
| NA | – | 2 | – | 0 |
| Sibling pairs | Sibling pairs | |||
| Sex match (donor/recipient) | ||||
| Male/male | 30 | 14 | ||
| Female/female | 13 | 3 | ||
| Male/female | 14 | 4 | ||
| Female/male | 28 | 11 | ||
| CMV match (donor/recipient) | ||||
| Negative/negative | 18 | 13 | ||
| Positive/positive | 25 | 8 | ||
| Negative/positive | 13 | 3 | ||
| Positive/negative | 13 | 6 | ||
| NA | 16 | 2 | ||
